Sumgen Biotech's Innovative injectable antibody SG301 Has Completed the First Dose for the First Patient In Phase Ⅲ Clinical Trial

date:2024-06-15      source:

Hangzhou, China - June 14, 2024 - Hangzhou Sumgen Biotech Co., Ltd (hereinafter referred to as "Sumgen Biotech") is delighted to announce the successful administration of the first dose In Phase Clinical Trial of our innovative drug SG301 injection. This marks another key milestone in the clinical study.

This Phase III clinical trial aims to evaluate the efficacy and safety of SG301 Injection in combination with pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma.The study was led by Professor Depei Wu ,Professor Chengcheng Fu from the First Affiliated Hospital of Soochow University and Professor Wenming Chen from Beijing Chaoyang Hospital affiliated with Capital Medical University. The trial is set to take place in roughly 40 centers across the country and serves as a crucial clinical study prior to the market approval of SG301 Injection.

Copyright Rm. 301, F3, Building C, Block 2, No. 688, Bin'an Road, Changhe Zhejiang ICP Filing No. 18039044